# AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma

> **NCT03893903** · PHASE1 · COMPLETED · sponsor: **German Cancer Research Center** · enrollment: 69 (actual)

## Conditions studied

- Malignant Glioma

## Interventions

- **DRUG:** IDH1R132H peptide vaccine
- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT03893903
- **Lead sponsor:** German Cancer Research Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-19
- **Primary completion:** 2024-09-20
- **Final completion:** 2024-09-20
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2025-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03893903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03893903, "AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03893903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*